ArticleAnalytical science advances2025
Comparison Between a New PSA Assay With the Well-Established Beckman Coulter Immunoassay: A Preliminary Report.
Article in Analytical science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Electrocatalytically Amplified Immunosensing Enabled by Titanium Oxynitride-Supported Ru Nanodots on Graphene Oxide Hybrid Architecture.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate-specific antigen (PSA) is a critical biomarker for prostate cancer (PCa) patient clinical management. In this study, we sought to compare three different immunoassays (CLIA): Beckman Coulter Access Hybritech (PSA-B) (reference method), Immulite 2000 PSA (PSA-I) and the newly introduced Atellica IM PSA assay (PSA-A). We selected serum samples from our routine clinical testing at University Hospital Federico II between April and May 2024 from 104 men with a median age of 66 years (interquartile range = 57-74). Total PSA was determined using three different assays: PSA-B, PSA-A and PSA-I. A significant correlation between PSA-B and PSA-I assays was found for samples in the overall population (Spearman
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.